文献速递慢性肾脏病

慢性肾脏病导致脑内小胶质细胞钾外流与炎症小体激活

Chronic kidney disease leads to microglial potassium efflux and inflammasome activation in the brain.
PubMed 文献 · Kidney Int · 2024-07-30

该研究结合小鼠模型、单细胞分析、人类样本和体外实验,发现慢性肾脏病(CKD)破坏血脑屏障,使小胶质细胞钙稳态失衡并通过KCa3.1通道增强钾外流,进而激活p38-MAPK和IL-1β成熟。抑制KCa3.1或阻断IL-1R1信号可改善CKD小鼠的认知障碍,提示小胶质细胞钾外流是CKD相关认知损伤的可干预机制。

要点

  • CKD通过破坏血脑屏障和微胶质细胞钾外流触发神经炎症。
  • KCa3.1抑制剂TRAM34或IL-1R1拮抗剂anakinra可改善CKD小鼠认知。
  • 神经元IL-1R1缺失可预防CKD导致的神经元钾周转下降和认知障碍。

核心结论

  • CKD中小胶质细胞钾外流触发其激活,促进IL-1β释放和IL-1R1介导的神经元功能障碍,导致认知损伤。

研究设计与样本

  • 研究使用小鼠模型(包括神经元特异性IL-1R1缺陷小鼠)、单核RNA测序、单细胞铊自显影、人类样本和体外实验。

主要发现

  • CKD在体外破坏脑内皮细胞屏障,在体内破坏血脑屏障。
  • 尿毒症条件损害小胶质细胞钙稳态,通过钙依赖性通道KCa3.1增强小胶质细胞钾外流,并诱导p38-MAPK相关的IL-1β成熟。
  • 使用KCa3.1特异性抑制剂TRAM34恢复小胶质细胞钾稳态,改善CKD触发的认知障碍。
  • 使用anakinra抑制IL-1R1或遗传性消除神经元IL-1R1表达,可预防CKD介导的神经元钾周转减少和CKD诱导的认知障碍。

关键数值与推荐

  • 在CKD小鼠中,通过预防小胶质细胞激活或抑制神经元IL-1R信号可改善认知障碍。

临床怎么用

  • 针对小胶质细胞KCa3.1或IL-1R1信号可能成为改善CKD相关认知障碍的新治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cognitive impairment is common in extracerebral diseases such as chronic kidney disease (CKD). Kidney transplantation reverses cognitive impairment, indicating that cognitive impairment driven by CKD is therapeutically amendable. However, we lack mechanistic insights allowing development of targeted therapies. Using a combination of mouse models (including mice with neuron-specific IL-1R1 deficiency), single cell analyses (single-nuclei RNA-sequencing and single-cell thallium autometallography), human samples and in vitro experiments we demonstrate that microglia activation impairs neuronal potassium homeostasis and cognition in CKD. CKD disrupts the barrier of brain endothelial cells in vitro and the blood-brain barrier in vivo, establishing that the uremic state modifies vascular permeability in the brain. Exposure to uremic conditions impairs calcium homeostasis in microglia, enhances microglial potassium efflux via the calcium-dependent channel KCa3.1, and induces p38-MAPK associated IL-1β maturation in microglia. Restoring potassium homeostasis in microglia using a KCa3.1-specific inhibitor (TRAM34) improves CKD-triggered cognitive impairment. Likewise, inhibition of the IL-1β receptor 1 (IL-1R1) using anakinra or genetically abolishing neuronal IL-1R1 expression in neurons prevent CKD-mediated reduced neuronal potassium turnover and CKD-induced impaired cognition. Accordingly, in CKD mice, impaired cognition can be ameliorated by either preventing microglia activation or inhibiting IL-1R-signaling in neurons. Thus, our data suggest that potassium efflux from microglia triggers their activation, which promotes microglia IL-1β release and IL-1R1-mediated neuronal dysfunction in CKD. Hence, our study provides new mechanistic insight into cognitive impairment in association with CKD and identifies possible new therapeutic approaches.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Zimmermann S, Mathew A, Bondareva O, et al. Chronic kidney disease leads to microglial potassium efflux and inflammasome activation in the brain. Kidney Int. 2024. PMID: 39089576. doi:10.1016/j.kint.2024.06.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。